New AI genomics platform targets kidney and cardiorenal disease
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered…
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.




